Trial · NCT00312208
Adverse events350
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 350
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Allergic reaction | General disorders | Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) | 172 | 1,634 | |
| other | Allergic reaction | General disorders | Docetaxel + Doxorubicin and Cyclophosphamide (TAC) | 190 | 1,635 | |
| other | Alopecia | Skin and subcutaneous tissue disorders | Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) | 1,601 | 1,634 | |
| other | Alopecia | Skin and subcutaneous tissue disorders | Docetaxel + Doxorubicin and Cyclophosphamide (TAC) | 1,587 | 1,635 | |
| other | Anemia | Blood and lymphatic system disorders | Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) | 461 | 1,634 | |
| other | Anemia | Blood and lymphatic system disorders | Docetaxel + Doxorubicin and Cyclophosphamide (TAC) | 658 | 1,635 | |
| other | Anorexia | Gastrointestinal disorders | Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) | 370 | 1,634 | |
| other | Anorexia | Gastrointestinal disorders | Docetaxel + Doxorubicin and Cyclophosphamide (TAC) | 376 | 1,635 | |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) | 602 | 1,634 | |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Docetaxel + Doxorubicin and Cyclophosphamide (TAC) | 382 | 1,635 | |
| other | Asthenia | Musculoskeletal and connective tissue disorders | Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) | 1,328 | 1,634 | |
| other | Asthenia | Musculoskeletal and connective tissue disorders | Docetaxel + Doxorubicin and Cyclophosphamide (TAC) | 1,310 | 1,635 | |
| other | Conjunctivitis | Eye disorders | Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) | 176 | 1,634 | |
| other | Conjunctivitis | Eye disorders | Docetaxel + Doxorubicin and Cyclophosphamide (TAC) | 131 | 1,635 | |
| other | Constipation | Gastrointestinal disorders | Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) | 599 | 1,634 | |
| other | Constipation | Gastrointestinal disorders | Docetaxel + Doxorubicin and Cyclophosphamide (TAC) | 555 | 1,635 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) | 211 | 1,634 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Docetaxel + Doxorubicin and Cyclophosphamide (TAC) | 222 | 1,635 | |
| other | Depression | Nervous system disorders | Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) | 160 | 1,634 | |
| other | Depression | Nervous system disorders | Docetaxel + Doxorubicin and Cyclophosphamide (TAC) | 132 | 1,635 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00312208/events